Actitrexx raises €4.0M Pre-Seed round
4 October 2016· Mainz, Germany· health, biotech, cell_therapy, b2b, deep_hardware
The funding supported Phase I of the GO-Bio start-up initiative, focused on the preclinical development of activated regulatory T cells and biomarker analysis prior to the company's spin-off.
Investors
LeadGerman Federal Ministry of Education and Research
About Actitrexx
Stage
Seed
Headquarters
Mainz, Germany
Founded
2020
Team Size
6–20
Sectors
healthbiotechcell_therapyb2bdeep_hardware
Source: https://www.go-bio.de/de/projekte/hiv-protein-zur-milderung-von-transplantatabstossungen.html